What is Kevzara?
Kevzara (sarilumab) is a prescription biologic drug that blocks interleukin-6 receptors to reduce inflammation. Sanofi and Regeneron make it. The FDA first approved it in 2017 for adults with moderately to severely active rheumatoid arthritis (RA) who haven't responded well to one or more tumor necrosis factor (TNF) inhibitors.[1]
How does Kevzara treat rheumatoid arthritis?
It works by targeting IL-6, a protein that drives joint inflammation and damage in RA. Patients take it as a subcutaneous injection every two weeks, either alone or with methotrexate. Clinical trials showed it reduces signs and symptoms, improves physical function, and slows joint damage progression compared to placebo.[1][2]
What is Kevzara approved for besides RA?
In 2021, the FDA granted emergency use authorization for hospitalized adults with COVID-19 needing supplemental oxygen, high-flow oxygen, or mechanical ventilation. It lowers the risk of progressing to intubation or death when used with other treatments like remdesivir or steroids. Full approval for this use followed in some regions, but check current labels as guidance evolved post-pandemic.[1][3]
Who should avoid Kevzara?
It's not for people with active infections, including tuberculosis. Warnings include risks of serious infections, gastrointestinal perforations, and lab abnormalities like low neutrophil counts. Live vaccines are off-limits during treatment. Doctors monitor bloodwork regularly.[1]
How much does Kevzara cost?
List prices vary by dose and location, but a 28-week supply for RA often exceeds $40,000 before insurance or assistance programs. Patient support from Sanofi covers copays for eligible U.S. patients.[4]
When do Kevzara patents expire?
Key U.S. patents protect sarilumab until at least 2031, with some formulation patents extending to 2033. No biosimilars are approved yet, but challenges are ongoing. Track updates on DrugPatentWatch.com.[5]
[1]: FDA Kevzara Label
[2]: NEJM Trial on Sarilumab for RA
[3]: FDA EUA for COVID-19
[4]: Sanofi Patient Assistance
[5]: DrugPatentWatch: Kevzara